Abigail Lewis, Content Intern

In this Q&A, LENZ CFO Dan Chevallard on Vizz's ECP momentum, telehealth expansion, and the global push to end reading glasses for presbyopia.

The new patient, secured by Provectus and VisiRose, supports a light-independent rose bengal eye drop that fights MRSA and other drug-resistant keratitis, erases biofilms, and enables self-administered treatment.

A midyear look at 2026's biggest optometry findings, from myopia control research to safety signals on red light therapy and semaglutide.

Optometry's meetings thus far reveal a field in motion: earlier glaucoma intervention, an expanding dry eye pipeline, breakthrough myopia data, and sharper contact lens and retinal evaluation.

A summary of major FDA approvals and CRLs in eye care from the first half of 2026.

Clinical trial data support the Deseyne contact lens, the first FDA-designated EDOF soft contact lens, as a new daily disposable option for presbyopia.

Preservative-free bimatoprost gel now offers once-daily glaucoma and ocular hypertension IOP reduction, aiming to boost comfort, tolerability, and long-term adherence.

Mark Wells, OD, weighs in on the new parameter range expected for the Acuvue Oasys 1-Day for Astigmatism lens.

New preservative-free cyclosporine 0.05% single-use drops target dry eye inflammation, dosing, and safety.

New phase 3 trial tests rhNGF eye drops for persistent corneal epithelial defects, aiming for full healing and a first approved PCED therapy.

The investment will expand ACUVUE contact lens manufacturing and distribution in Jacksonville, improving supply chain stability for optometrists by 2028.

Epion completes phase 3 follow-up for EpiSmart epi-on corneal cross-linking in keratoconus, advancing toward FDA NDA and a less painful alternative.

Oculis launches a genotype-guided dry eye trial testing licaminlimab eye drops, targeting TNFR1 patients and measuring Day 29 ocular discomfort improvement.

The free web-based tool guides eye care providers through evidence-based amblyopia diagnosis and treatment without requiring pediatric subspecialty training.

New findings confirm TearCare's long-term effectiveness for dry eye disease, showing significant patient improvements with minimal treatments over 2 years.

The partnership marks a major step toward expanding global access to targeted treatments for this vision-threatening condition, according to a news release.